ライフサイエンスコーパス: carcinoma

1 py vs no therapy with risk of hepatocellular carcinoma.

2 with platinum-refractory advanced urothelial carcinoma.

3 nd possibly also of pharyngeal squamous cell carcinoma.

4 clinical surveillance for early detection of carcinoma.

5 argeting c-Myc for degradation in human lung carcinoma.

6 inal (GI)-related cancers, including gastric carcinoma.

7 premetastatic niche) in the models of breast carcinoma.

8 epithelial cell-derived nasopharyngeal cell carcinoma.

9 th metastatic platinum-refractory urothelial carcinoma.

10 or the treatment of VHL-deficient renal cell carcinoma.

11 angitis and a newly diagnosed hepatocellular carcinoma.

12 tocyte growth and progress to hepatocellular carcinoma.

13 causes Burkitt's lymphoma and nasopharyngeal carcinoma.

14 It is called squamous cell prostate carcinoma.

15 mab for the treatment of advanced renal cell carcinoma.

16 oma, urothelial carcinoma, and squamous cell carcinoma.

17 ng adenocarcinoma to melanoma and basal cell carcinoma.

18 fenib in patients with metastatic renal cell carcinoma.

19 in platinum-refractory, advanced urothelial carcinoma.

20 7 with cirrhosis and 113 with hepatocellular carcinoma.

21 patient with extremely aggressive colorectal carcinoma.

22 n locally advanced and metastatic urothelial carcinoma.

23 e 6-29) were enrolled, 26 had hepatocellular carcinoma.

24 FDG PET than the more common invasive ductal carcinoma.

25 s of mouse and human cutaneous squamous cell carcinoma.

26 s, hepatic decompensation, or hepatocellular carcinoma.

27 in patients with unresectable hepatocellular carcinoma.

28 of ~30 cancer cells from a recurrent ovarian carcinoma.

29 th locally advanced or metastatic urothelial carcinoma.

30 (lncRNA) which is induced in hepatocellular carcinoma.

31 vival in patients with metastatic urothelial carcinoma.

32 for preoperative demarcation of keratinocyte carcinomas.

33 uctal adenocarcinomas and 40% of acinar cell carcinomas.

34 rgeted agents used to treat other renal cell carcinomas.

35 c and genetic features of human adenomas and carcinomas.

36 se resemblance to human uterine endometrioid carcinomas.

37 plastic lesions into invasive and metastatic carcinomas.

38 for the treatment of cutaneous squamous cell carcinomas.

39 tients (melanoma, 1; lung, 4; hepatocellular carcinoma, 1).

40 ormation from 12 human colorectal tumors (11 carcinomas, 1 adenoma) obtained through saturation micro

41 fter Kaposi sarcoma (685.68) and Merkel cell carcinoma (117.23).

42 tridium difficile(1), promote hepatocellular carcinoma(2) and modulate host metabolism via the G-prot

43 0.40 [95% CI, 0.28-0.56) and hepatocellular carcinoma (20 studies, n = 84 491; pooled HR, 0.29 [95%

44 While 75% of all keratinocyte carcinoma (4 million annual cases in the United States)

45 umours, lung and kidney cysts and renal cell carcinoma(6,7).

46 rs, a papillary transitional cell renal cell carcinoma, a duodenal carcinoma, two metachronous colore

47 Adrenocortical carcinomas (ACC) are rare and aggressive malignancies wi

48 o predict viable or nonviable hepatocellular carcinoma after ablation.

49 ee patients with BKPyV-associated urothelial carcinoma after renal transplantation.

50 Pre-treatment determination of renal cell carcinoma aggressiveness may help guide clinical decisio

51 eived radioiodine for differentiated thyroid carcinoma also showed interstitial pneumonia on SPECT/CT

52 exceptions were observed for nasopharyngeal carcinoma, an EBV-associated cancer, and CLL/SLL forms o

53 o test this hypothesis, HUH-7 hepatocellular carcinoma and AML12 normal hepatocytes were incubated wi

54 (encompassing MYC) in clear cell renal cell carcinoma and chromosome 11q13.3 (encompassing CCND1) in

55 co-primary outcomes (incident primary liver carcinoma and death from any cause) were ascertained fro

56 ma was also observed in non-invasive bladder carcinoma and I-BLCA.

57 ing, we estimated the risk of hepatocellular carcinoma and liver-related mortality, accounting for co

58 a significantly lower risk of hepatocellular carcinoma and lower liver-related mortality than no use

59 Liver carcinoma and mortality risks are increased in individua

60 reatment in both head and neck squamous cell carcinoma and non-small cell lung cancer.

61 decrease the risk of laryngeal squamous cell carcinoma and possibly also of pharyngeal squamous cell

62 had metastatic castration-resistant prostate carcinoma and who had exhausted available therapy option

63 in hepatocyte growth biology, hepatocellular carcinoma, and HCV pathogenesis.

64 , including small cell carcinoma, urothelial carcinoma, and squamous cell carcinoma.

65 e transition from in situ to invasive breast carcinoma, and, accordingly, high EPN3 levels are detect

66 mesenchymal transition in a subset of common carcinomas, and in chordoma, a rare cancer showing notoc

67 denal carcinoma, two metachronous colorectal carcinomas, and multi-regional sampling in a triple-nega

68 inib versus sunitinib in advanced renal cell carcinoma (aRCC).

69 al characteristics divergent from urothelial carcinoma are extreme examples of tumour heterogeneity.

70 at more than one-fifth of ovarian and breast carcinomas are associated with inherited risk.

71 The permanent activation of hepatocellular carcinoma-associated proto-oncogenes such as c-Jun and a

72 l patient was diagnosed with invasive ductal carcinoma at the time of 6-month follow-up.

73 rms patient prognosis in primary Merkel cell carcinoma beyond the T-cell density.

74 om liver disease (cirrhosis + hepatocellular carcinoma), but data are lacking at the local level (eg,

75 -line treatment for some types of colorectal carcinoma, causes peripheral neuropathic pain in patient

76 odels of CAIX-positive clear cell renal cell carcinoma (ccRCC) and colorectal cancer.

77 r features that define clear cell renal cell carcinoma (ccRCC) initiation and progression are being i

78 e most prevalent type, clear cell renal cell carcinoma (ccRCC), is characterized by genetic mutations

79 a tumor-suppressor in clear cell renal cell carcinoma (ccRCC), primarily based on functional prolife

80 is highly expressed in clear cell renal cell carcinoma (ccRCC), where SLC2A3 expression is associated

81 inactivation, such as clear-cell renal cell carcinoma (ccRCC).

82 ve of poor survival in clear cell renal cell carcinoma (ccRCC).

83 al tumor suppressor in clear cell renal cell carcinomas (ccRCCs).

84 ISPR-Cas9-mediated screen using a human lung carcinoma cell line and identify semaphorin (SEMA) 6A an

85 21 enhances the proliferation of MCF7 breast carcinoma cells and counteracts the decrease in cell pro

86 nes in oral fibroblasts, oral human squamous carcinoma cells and macrophages in vitro.

87 We demonstrate that breast carcinoma cells exposed to radiation shed TMPs containin

88 The carcinoma cells express enhanced green fluorescent prote

89 uppressor using a xenograft mouse model with carcinoma cells harboring defined ARHGAP35 alterations.

90 ng has key roles in cancer progression: most carcinoma cells have inactivated their epithelial antipr

91 re-cultured with TMPs from irradiated breast carcinoma cells increases tumor growth rates in mice rec

92 In vitro, restoration of p190A expression in carcinoma cells promotes contact inhibition of prolifera

93 ally, our data from NCI-H295R adrenocortical carcinoma cells suggest that adrenocortical tumors may e

94 acts as a metabolism modulator in pancreatic carcinoma cells through the regulation of argininosuccin

95 s increased the sensitivity of mouse mammary carcinoma cells to radiation therapy in vitro and in viv

96 Here, squamous carcinoma cells were seeded at different starting cell n

97 In cultured A549 lung carcinoma cells, anakinra, PAS600-IL-1Ra, and PAS800-IL-

98 extracellular vesicle production by mammary carcinoma cells.

99 enriched in a subset of human hepatocellular carcinomas characterized by comparatively poor prognosis

100 V, BKV and EBV in patient-derived colorectal carcinoma (CRC) cells typifying all molecular subtypes o

101 ulated in about half of the human colorectal carcinomas (CRC) and in other cancers.

102 ancer (NMSC) such as cutaneous squamous cell carcinoma (cSCC) is caused by solar ultraviolet (SUV) ex

103 skin cancer such as cutaneous squamous cell carcinoma (cSCC) is the most common form of cancer and c

104 ) and desmoplasia on cutaneous squamous cell carcinoma (CSCC) recurrence and metastasis.

105 ient with metastatic cutaneous squamous cell carcinoma (CSCC).

106 Cutaneous squamous cell carcinoma (cuSCC) is the second most common skin cancer

107 ified by International Metastatic Renal Cell Carcinoma Database Consortium risk status and geographic

108 tients had higher incidence of squamous cell carcinoma despite lower prevalence of behavioral risk fa

109 econd aggressive head and neck squamous cell carcinoma diagnosed 15 weeks postinclusion.

110 c examinations, with a similar percentage of carcinomas diagnosed.

111 sts (CAFs) in the microenvironment of murine carcinomas, each endowed with unique phenotypic features

112 Endometrioid ovarian carcinoma (EnOC) demonstrates substantial clinical and m

113 In human breast carcinomas, epithelial-to-mesenchymal transition (EMT) u

114 Equine penile squamous cell carcinoma (EpSCC) is a relatively common cutaneous neopl

115 Esophageal squamous cell carcinoma (ESCC) is among the most aggressive and fatal

116 on of patients with esophageal squamous cell carcinoma (ESCC) who do not benefit from standard chemor

117 and pathogenesis of esophageal squamous cell carcinoma (ESCC).

118 patients with mUC and metastatic renal cell carcinoma, even in tumors that were classically CD8(+) T

119 reas, lung adenocarcinoma, and squamous cell carcinoma) for the frequency of codon mutations of 10 Rh

120 ational Cancer Database with invasive breast carcinoma from 2012-2016 that underwent upfront lumpecto

121 ng the diagnosis of undifferentiated gastric carcinoma from the biopsy taken from the ulcerated lesio

122 for patients with an advanced hepatocellular carcinoma from the German statutory health insurance per

123 th locally advanced or metastatic urothelial carcinoma, from 221 sites in 35 countries, were randomly

124 utarate production antagonizes squamous cell carcinoma growth.

125 nd MRI-guided cryoablation of cT1 renal cell carcinoma had similar excellent intermediate- and long-t

126 Patients with advanced endometrial carcinoma have limited treatment options.

127 ith locally advanced cutaneous squamous cell carcinoma have poor prognosis with conventional systemic

128 For instance, ALK-rearranged renal cell carcinomas have shown responses to alectinib and crizoti

129 " (MTM) histologic subtype of hepatocellular carcinoma (HCC) (MTM-HCC) represents an aggressive form

130 tologic type of liver cancer, hepatocellular carcinoma (HCC) accounts for the great majority of liver

131 s frequently overexpressed in hepatocellular carcinoma (HCC) and is an independent diagnostic marker

132 r disease have lower rates of hepatocellular carcinoma (HCC) as compared to men; it is unknown if the

133 l chemoembolization (TACE) in hepatocellular carcinoma (HCC) because of the potential for profound ad

134 w that activated AKT in human hepatocellular carcinoma (HCC) cells phosphorylates cytosolic phosphoen

135 iver function and facilitates hepatocellular carcinoma (HCC) development, representing a major threat

136 There are limited data on hepatocellular carcinoma (HCC) growth patterns, particularly in Western

137 ion on the risk of developing hepatocellular carcinoma (HCC) in HCV-infected patients who achieve sus

138 Hepatocellular carcinoma (HCC) is an increasingly common indication for

139 Hepatocellular carcinoma (HCC) is clearly age-related and represents on

140 Hepatocellular carcinoma (HCC) is one of most common cancers worldwide,

141 Hepatocellular carcinoma (HCC) is the third most frequent cause of canc

142 h hepatitis C virus (HCV) and hepatocellular carcinoma (HCC) listed for liver transplantation (LT).

143 rterial embolization (TAE) of hepatocellular carcinoma (HCC) provides a compelling clinical correlate

144 b (SOR) is currently used for hepatocellular carcinoma (HCC) recurring after liver transplantation (L

145 Hepatocellular carcinoma (HCC) represents the sixth most commonly diagn

146 Hepatocellular carcinoma (HCC) surveillance is associated with early tu

147 s aerobic glycolysis in human hepatocellular carcinoma (HCC) through nuclear relocalization of pyruva

148 ulting cell debris stimulates hepatocellular carcinoma (HCC) tumor growth via an "eicosanoid and cyto

149 ey roles in tumors, including hepatocellular carcinoma (HCC), a malignancy with no effective treatmen

150 ational landscape of advanced hepatocellular carcinoma (HCC), and predictive biomarkers of response t

151 e marked sexual dimorphism of hepatocellular carcinoma (HCC), sex hormone receptor signaling has been

152 t progression in the study of hepatocellular carcinoma (HCC), the role of the proteasome in regulatin

153 ce is predominantly driven by hepatocellular carcinoma (HCC), which accounts for 75% of LC cases.

154 ter liver transplantation for hepatocellular carcinoma (HCC), with and without hypothermic oxygenated

155 ncies including viral-derived hepatocellular carcinoma (HCC).

156 often aberrantly expressed in Hepatocellular Carcinoma (HCC).

157 the tumor immune response in hepatocellular carcinoma (HCC).

158 plants (LT) are performed for hepatocellular carcinoma (HCC).

159 rexpressed in mouse and human hepatocellular carcinoma (HCC).

160 al role in the progression of hepatocellular carcinoma (HCC).

161 tty liver disease (NAFLD) and hepatocellular carcinoma (HCC).

162 in diverse cancers, including hepatocellular carcinoma (HCC).

163 the major causal factors for hepatocellular carcinoma (HCC).

164 vise a strategy for targeting hepatocellular carcinoma (HCC, one of the deadliest malignancies).

165 r liver-related events (i.e., hepatocellular carcinoma [HCC], hepatic decompensation, or liver-relate

166 Background Intermediate stage hepatocellular carcinomas (HCCs) are treated by inducing ischemic cell

167 Most hepatocellular carcinomas (HCCs) develop in patients with chronic hepat

168 Many high-grade serous carcinomas (HGSCs) likely originate in the distal region

169 High-grade serous ovarian carcinoma (HGSOC) is the most lethal gynecologic maligna

170 High-grade serous ovarian carcinoma (HGSOC) is the most lethal gynecological cance

171 In human breast carcinoma, high Skp2 and low Tpl2 expression are associa

172 Head and neck squamous cell carcinoma (HNSCC) associated with high-risk human papill

173 Interrogation of head and neck squamous cell carcinoma (HNSCC) cell lines and patient tumors showed t

174 Head and neck squamous cell carcinoma (HNSCC) is a disease of significant morbidity

175 nant features of head and neck squamous cell carcinoma (HNSCC) may be derived from the presence of st

176 in patients with head and neck squamous cell carcinoma (HNSCC).

177 tivity of CBI in head and neck squamous cell carcinoma (HNSCC).

178 rexpressed in head and neck of squamous cell carcinoma (HNSCC).

179 tic or recurrent head and neck squamous cell carcinoma (HNSCC).

180 ionally advanced head and neck squamous cell carcinoma (HNSCC; stage III-IV according to the Union fo

181 ate incidence of head and neck squamous cell carcinomas (HNSCC), including oral cavity and pharynx (O

182 undefined in the head and neck squamous cell carcinomas (HNSCCs).

183 lood vasculature from human invasive bladder carcinoma (I-BLCA) and normal bladder tissue vasculature

184 ence of cases of invasive anal squamous-cell carcinoma (IASCC) in persons with HIV-1, we performed a

185 Invasive lobular carcinoma (ILC) demonstrates lower conspicuity on (18)F-

186 diagnosed in 62% of the patients (small-cell carcinoma in 83%).

187 rescent PARP1 inhibitor can also detect oral carcinoma in a patient when applied as a mouthwash, and

188 dvanced and/or metastatic anaplastic thyroid carcinoma in a phase II cohort of the study.

189 EtHOBA inhibited gastric carcinoma in infected INS-GAS mice and gerbils and atten

190 Testing of ductal carcinoma in situ (DCIS) for ER is recommended to determ

191 expression was lost in microdissected ductal carcinoma in situ (DCIS) from patients with luminal and

192 Ductal Carcinoma In Situ (DCIS) represents a significant fracti

193 believed to evolve from non-invasive ductal carcinoma in situ (DCIS).

194 55 (53.4%) of 103 patients with carcinoma in situ (with or without a high-grade Ta or T1

195 with completely excised non-low-risk ductal carcinoma in situ were randomly assigned, by use of a mi

196 ging fibrosis, cirrhosis, and hepatocellular carcinoma, in this population.

197 rams induced by cMYC, a response that blunts carcinoma initiation, but does not perturb the normal pr

198 High-grade serous ovarian carcinoma is characterised by TP53 mutation and extensiv

199 or patients with locally advanced esophageal carcinoma is recommended.

200 ted with other malignancies (e.g. renal cell carcinoma), little is known about the role of this varia

201 Merkel cell carcinoma (MCC) is a rare, aggressive skin cancer common

202 Merkel cell carcinoma (MCC) is a rare, highly aggressive skin cancer

203 ly integrated in 80% of cases of Merkel cell carcinoma (MCC), a rare but aggressive form of human ski

204 t the etiologic role of MCPyV in Merkel cell carcinoma (MCC), an extremely lethal form of skin cancer

205 Muscle-invasive bladder carcinomas (MIBCs) are aggressive genitourinary malignan

206 hermia in a neu deletion (NDL) mouse mammary carcinoma model (Her2(+), ER/PR negative).

207 itumorally in vivo in the EMT6 mouse mammary carcinoma model, OxLys-SNAs significantly increase the p

208 growth in the xenograft human hepatocellular carcinoma mouse model.

209 In B16-F10 melanoma and MC38 colorectal carcinoma mouse models, reprogramming nanoparticles in c

210 oIpi) in patients with metastatic urothelial carcinoma (mUC) and other genitourinary (GU) malignances

211 noma (EA; n = 855), esophageal squamous cell carcinoma (n = 267), and gastric cancer (cardia: n = 603

212 with stage IV lung carcinomas (n=24), renal carcinomas (n=11), or melanoma (n=44) treated with immun

213 vely included 79 patients with stage IV lung carcinomas (n=24), renal carcinomas (n=11), or melanoma

214 ve ablation was applied to 42 hepatocellular carcinoma nodules in 31 patients.

215 Nasopharyngeal carcinoma (NPC) is a highly metastatic cancer that is co

216 from patients with oral cavity squamous cell carcinoma (OCSCC) in order to map metabologenomic events

217 ed independently associated with the risk of carcinoma (odds ratio, 1.97; 95% confidence interval, 1.

218 Small cell carcinoma of the bladder (SCCB) is a rare and lethal phe

219 a, squamous cell carcinoma, or adenosquamous carcinoma of the cervix, with an Eastern Cooperative Onc

220 e timing of surgery after completed nCRT for carcinoma of the esophagus or esophagogastric junction,

221 mary cutaneous signet-ring cell/histiocytoid carcinoma of the eyelid is an extremely rare but aggress

222 oma (RCC), endometrial cancer, squamous cell carcinoma of the head and neck (SCCHN), melanoma, non-sm

223 larly to confirm the presence of intraductal carcinoma of the prostate (IDC-P), an aggressive histopa

224 high risks for second in situ squamous cell carcinoma of the skin were found after Kaposi sarcoma (6

225 1 was on pembrolizumab for his squamous cell carcinoma of the skin, whereas patient 2 received RLT se

226 for each invasive and in situ squamous cell carcinoma of the skin.

227 Urothelial carcinomas of the upper urinary tract (UTUCs) are rare,

228 er stage-for-stage prognosis than urothelial carcinomas of the urinary bladder.

229 fferentiation between follicular adenoma and carcinoma on Bethesda type IV lesions.

230 The incidence of oropharyngeal squamous cell carcinoma (OPSCC) has been rapidly increasing.

231 Oropharyngeal squamous cell carcinoma (OPSCC) incidence is increasing at a nearly ep

232 (HPV)-associated oropharyngeal squamous cell carcinoma (OPSCC).

233 r solid tumors like esophageal squamous-cell carcinoma or glioma.

234 n, IA2, or IB1 adenocarcinoma, squamous cell carcinoma, or adenosquamous carcinoma of the cervix, wit

235 w therapeutic targets for oral squamous cell carcinoma (OSCC) are urgently needed.

236 Oral squamous cell carcinoma (OSCC) is one of the most painful cancers, whi

237 Oral squamous cell carcinoma (OSCC) is the most common malignant tumor that

238 he heterogeneity of human oral squamous cell carcinoma (OSCC), we have performed genomic analysis of

239 Ovarian carcinoma (OvC) remains a major therapeutic challenge du

240 nd-line treatment of advanced hepatocellular carcinoma over a lifetime horizon.

241 (8/8) in detecting high-grade dysplasias and carcinomas over white-light detection alone with 75% (6/

242 Metastatic prostate carcinoma overexpresses prostate-specific membrane antig

243 and were more associated with squamous cell carcinomas (P = 0.04).

244 inic keratosis, a precursor of squamous cell carcinoma, p16(INK4a)-expressing cells are found adjacen

245 Methods: In a relevant renal cell carcinoma patient-derived xenograft model, we use the (8

246 ab-Gem and survival in metastatic pancreatic carcinoma patients.

247 nical presentation and workup of parathyroid carcinoma (PC) and determine its clinical prognostic par

248 Prostate carcinoma (PCa) is the second most commonly diagnosed ca

249 Pancreatic ductal carcinoma (PDAC) is a highly lethal cancer, and early de

250 delete essential autophagy regulators during carcinoma progression.

251 multifocal leukoencephalopathy, Merkel cell carcinoma, pruritic rash or trichodysplasia spinulosa.

252 Papillary thyroid carcinomas (PTCs) account for 90% of human thyroid cance

253 The size of invasive carcinomas ranged from 0.6-1.0 cm (mean, 0.5 cm).

254 our initiation and progression in renal cell carcinoma (RCC) and three oncometabolites - fumarate, su

255 treatment landscape of metastatic renal cell carcinoma (RCC) has been revolutionized over the past tw

256 Renal cell carcinoma (RCC) incidence is increasing worldwide.

257 Human renal cell carcinoma (RCC) tumors were stained for the NK cell rece

258 Eligible patients had metastatic renal cell carcinoma (RCC), endometrial cancer, squamous cell carci

259 obtained from three patients with renal cell carcinoma (RCC), were imaged.

260 nisms are only poorly analyzed in renal cell carcinoma (RCC).

261 re standard therapy in metastatic renal cell carcinoma (RCC).

262 mal kidney, renal oncocytoma, and renal cell carcinomas (RCC).

263 in most histological subtypes of renal cell carcinomas (RCCs) and carries a decidedly poor prognosis

264 r a patient cohort with advanced endometrial carcinoma receiving lenvatinib plus pembrolizumab in an

265 Renal medullary carcinoma (RMC) is a highly lethal malignancy that mainl

266 The genomic architecture of carcinomas, sarcomas and lymphomas arising in the same a

267 Epidermal squamous cell carcinoma (SCC) is a common and highly invasive form of

268 rbidities, lower proportion of squamous cell carcinoma (SCC), and more positive lymph nodes.

269 mphoma (seven patients, 15.6%), and prostate carcinoma (seven patients, 15.6%).

270 and mortality from cirrhosis, hepatocellular carcinoma, solid organ malignancies, diabetes mellitus,

271 ese progression-related signatures, and that carcinoma-specific signatures are predictive of survival

272 Sarcomatoid clear-cell renal cell carcinomas (sRCC) are associated with dismal prognosis.

273 ions, including serous tubal intraepithelial carcinoma (STIC), with genetic heterogeneity providing a

274 irectly induce cell death in CD40-expressing carcinomas, subsequently releasing tumour-specific antig

275 ho underwent potentially curative esophageal carcinoma surgery in 2011 to 2018, were included in this

276 level, the proliferation of invasive ductal carcinoma through breast tissue is beyond the range of s

277 Epithelial ovarian carcinoma tissues express high levels of tumor necrosis

278 nglioside isolated from malignant renal cell carcinoma tissues, is reported.

279 iew included 53 patients with hepatocellular carcinoma treated with radioembolization at our center.

280 n locally advanced inoperable hepatocellular carcinoma treated with TARE.

281 rvival and disease control in hepatocellular carcinoma treated with transarterial radioembolization w

282 Radioembolization in Advanced Hepatocellular Carcinoma trial.

283 rate the use of ClonArch on a hepatocellular carcinoma tumor with ~280 sequencing biopsies.

284 tional cell renal cell carcinoma, a duodenal carcinoma, two metachronous colorectal carcinomas, and m

285 s a potential oncogenic factor of urothelial carcinoma (UC) in renal transplant recipients.

286 re of tumor phenotypes, including small cell carcinoma, urothelial carcinoma, and squamous cell carci

287 Treatment of hepatocellular carcinomas using our glypican-3 (GPC3)-targeting human n

288 r cumulative probabilities of hepatocellular carcinoma, vascular events, and nonhepatic cancers were

289 ellular proliferation.IMPORTANCE Merkel cell carcinoma was first described in 1972 as a neuroendocrin

290 le, the risk of cirrhosis and hepatocellular carcinoma was reduced by 15% and 28%, respectively.

291 ma (83%); however, the rate of squamous cell carcinoma was significantly higher in females (35% vs 11

292 lid tumors, patients with anaplastic thyroid carcinoma were treated with spartalizumab, a humanized m

293 intestinal cancers, including hepatocellular carcinoma, which is currently undruggable.

294 h previously untreated metastatic urothelial carcinoma who benefit from treatment with immune checkpo

295 poor for patients with metastatic urothelial carcinoma who receive standard, first-line, platinum-bas

296 d, platinum-refractory metastatic urothelial carcinoma with measurable disease and bone metastases an

297 tures and developed low-grade serous ovarian carcinomas with 100% penetrance within 18 weeks.

298 MT mice, which spontaneously develop mammary carcinomas, with MC-deficient C57BL/6-Kit(W-sh/W-sh) (Ws

299 different from patients with hepatocellular carcinoma within Milan receiving exception point priorit

300 on remains the major cause of hepatocellular carcinoma worldwide, with more than half of HCC patients